Disease · EFO_0022959
hand eczema
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hand eczema. Diseases, record EFO_0022959. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0022959
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- hand eczema
- Open Targets ID
- EFO_0022959
- Other names
- hand dermatitis
- Highest stage of its drugs
- Phase 3, for 4 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DELGOCITINIB | CHEMBL4297507 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ALITRETINOIN | CHEMBL705 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PIMECROLIMUS | CHEMBL1200686 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACITRETIN | CHEMBL1131 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ABROCITINIB | CHEMBL3655081 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUSACITINIB | CHEMBL4594275 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK1 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 3 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| RARA | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/5914 | Drugs and targets |
| RARB | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/5915 | Drugs and targets |
| RARG | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/5916 | Drugs and targets |
| RXRA | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/6256 | Drugs and targets |
| RXRB | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/6257 | Drugs and targets |
| RXRG | Retinoid receptor | 2 | Retinoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/6258 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04949841 | Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials | Phase 3 | 801 | 2025-01-20 | Chronic Hand Eczema | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00817063 | Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema | Phase 3 | 599 | 2017-11-09 | Eczema | ALITRETINOIN | Its record names the disease | ClinicalTrials.gov |
| NCT05259722 | A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema | Phase 3 | 513 | 2025-03-14 | Chronic Hand Eczema | ALITRETINOIN, DELGOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04871711 | Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema | Phase 3 | 487 | 2024-09-23 | Chronic Hand Eczema | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03683719 | Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema | Phase 2 | 258 | 2021-04-19 | Chronic Hand Eczema | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03728504 | Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema | Phase 2 | 97 | 2023-05-09 | Chronic Hand Dermatitis | GUSACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00226707 | Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis | Phase 3 | 652 | Chronic Hand Dermatitis | PIMECROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT06004050 | A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema | Phase 3 | 362 | Chronic Hand Eczema | DELGOCITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00309621 | Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis | Phase 3 | 250 | Hand Dermatoses | ALITRETINOIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00519675 | Alitretinoin in the Treatment of Chronic Hand Eczema | Phase 3 | 150 | Eczema | ALITRETINOIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alitretinoin 30 mg vs Placebo: Number of Participants Who Responded as Per Patient Global Assessment (PaGA) at End-of-treatment | 117 of 298 | 41 of 298 | 596 | NCT00817063 | Trial comparisons |
| Alitretinoin 30 mg vs Placebo: deaths from any cause | 1 of 296 | 2 of 298 | 594 | NCT00817063 | Trial comparisons |
| Alitretinoin 30 mg vs Placebo: serious adverse events | 7 of 296 | 3 of 298 | 594 | NCT00817063 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: IGA-CHE TS at Week 12. | 68 of 250 | 42 of 253 | 503 | NCT05259722 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: deaths from any cause | 0 of 253 | 0 of 247 | 500 | NCT05259722 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: serious adverse events | 5 of 253 | 12 of 247 | 500 | NCT05259722 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule: HECSI-90 at Week 12 | 96 of 249 | 65 of 250 | 499 | NCT05259722 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Cream Vehicle: Number of Participants With IGA-CHE TS at Week 8 | 74 of 325 | 17 of 162 | 487 | NCT04871711 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Cream Vehicle: Number of Participants With HECSI-75 at Week 8 | 163 of 325 | 42 of 162 | 487 | NCT04871711 | Trial comparisons |
| Delgocitinib Cream 20 mg/g vs Cream Vehicle: Number of Participants With IGA-CHE TS at Week 4 | 50 of 325 | 8 of 162 | 487 | NCT04871711 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 40252681 | RESULT | 1 | PubMed |
| 39033766 | RESULT | 1 | PubMed |
| 41775339 | DERIVED | 1 | PubMed |
| 41240207 | DERIVED | 1 | PubMed |
| 40525591 | DERIVED | 1 | PubMed |
| 40186746 | DERIVED | 1 | PubMed |
| 40081663 | DERIVED | 1 | PubMed |
| 39760239 | DERIVED | 1 | PubMed |
| 39428453 | DERIVED | 1 | PubMed |
| 38507100 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0022959
GET https://conductscience.org/api/diseases/v1/EFO_0022959/comparisons?page=2